Navigation Links
Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
Date:6/26/2008

BOSTON, June 26 /PRNewswire-USNewswire/ -- Headache specialists meet today in Boston for the 50th annual meeting of the American Headache Society. Learn more about headache and face pain developments of the last 50 years -- including the top five advances in headaches -- and what researchers envision for the future.

For additional information, contact: Gina Czark at 312.558.1770, ext. 139 or gczark@pcipr.com or visit http://www.headachenews.org.

Among the topics being presented, include:

-- WHY PAIN BECOMES CHRONIC: Research shows previously unknown role certain

brain cells play in triggering chronic headaches for 9 million Americans

Think that pain medication is helping you ease the throbbing of a

headache? Think again. Researchers discovered neurons are not the only

carrier of pain signals to the brain. Glial cells, which outnumber

neurons 20:1, have been shown to prompt chronic pain in a variety of

ways, such as by a virus, nerve damage or even medication. Morphine and

other opiates also activate glial cells, which mean those drugs

you're taking to alleviate pain might actually be making it worse.

-- FIRST RIGOROUS TEST OF MAGNETIC STIMULATION DEVICE SHOWS PROMISE FOR

SHORT-CIRCUITING MIGRAINES: Research shows 7 million Americans could

benefit from this treatment

Imagine simply zapping away the pain at the onset of a migraine, instead

of gulping medication and waiting for relief. Researchers are presenting

encouraging results showing a portable transcranial magnetic stimulation

device would help an estimated 39 percent of migraine sufferers. The

device, about the size and weight of a hairdryer, works by placing it to

the back of the head and pushing a button twice, sending a very brief

magnetic field pulse into the brain. The 16-site multicenter,

randomized, double blind study is the first rigorous test of the

magnetic stimulation device.

-- STIMULATING THERAPY THAT HITS A NERVE: Early Research Shows New

Implanted Device Helps Alleviate Near-Daily Migraines

Stimulating a nerve might be just the ticket to help relieve the pain of

chronic migraine sufferers. Occipital nerve stimulation, in which an

implanted neurostimulator sends electrical impulses to the central

nervous system, has been shown to help 40 percent of near-daily migraine

sufferers who don't have success with standard pain medication.

Stimulating the occipital nerve, which ignites a tingling sensation,

appears to activate mechanisms that block the perception of pain in the

brain.


'/>"/>
SOURCE American Headache Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
2. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
3. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
4. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
7. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
8. Leading Immunologists Convene in Boston
9. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
10. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
11. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... HARRISBURG, Pa. , Dec. 8, 2016 /PRNewswire-USNewswire/ ... and Secretary of Drug and Alcohol Programs ... anxiety and insomnia medications, known as benzodiazepines, developed ... "Benzodiazepines are medications that are frequently ... "However, when they are used with opioid pain ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... 08, 2016 , ... STAT courier is pleased to announce that due to ... they are expanding their presence in Dallas. One of the most exciting parts for ... jobs to the Dallas and Forth Worth market. STAT takes pride in treating their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the ... Series B led by Canvas Ventures . Other investors include Nokia Growth Partners ... mobile platform to serve more consumers who are managing chronic conditions or ...
Breaking Medicine News(10 mins):